| Name | Title | Contact Details |
|---|---|---|
Sergey Tesler |
Executive Director, Global Regulatory Strategy, CMC | Profile |
Patrik Florencio |
SVP, Global Chief Compliance and Risk Officer | Profile |
Ellen Rosenberg |
Chief Legal Officer | Profile |
Heather Ramirez |
Executive Director - Lead Counsel US | Profile |
We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity.
Sun Pharma is the world`s fourth largest specialty generic pharmaceutical company and India`s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma`s global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.
Novis Pharmaceuticals is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.
Bioniche Pharma USA LLC is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.